Yajun Ruan1, Mingchao Li2, Tao Wang1, Jun Yang1, Ke Rao1, Shaogang Wang1, Weiming Yang1, Jihong Liu3, Zhangqun Ye1. 1. Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China. 2. Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China. Electronic address: chaoren149@163.com. 3. Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China; Institute of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China. Electronic address: jhliu@tjh.tjmu.edu.cn.
Abstract
INTRODUCTION: For patients with diabetes, erectile dysfunction (ED) is common and greatly affects quality of life. However, these patients often exhibit a poor response to first-line oral phosphodiesterase type 5 inhibitors. AIM: To investigate whether taurine, a sulfur-containing amino acid, affects diabetic ED (DED). METHODS: Type 1 diabetes mellitus was induced in male rats by using streptozotocin. After 12 weeks, an apomorphine test was conducted to confirm DED. Only rats with DED were administered taurine or vehicle for 4 weeks. Age-matched nondiabetic rats were administered saline intraperitoneally for 4 weeks. MAIN OUTCOME MEASURES: Erectile function was evaluated by electrical stimulation of the cavernous nerve. Histologic and molecular alterations of the corpus cavernosum also were analyzed. RESULTS: Erectile function was significantly reduced in the diabetic rats compared with in the nondiabetic rats, and was improved in the diabetic rats treated with taurine. The corpus cavernosum of the rats with DED exhibited severe fibrosis and decreased smooth muscle content. Deposition of extracellular matrix proteins was increased in the diabetic rats, while expression of endothelial nitric oxide synthase/cyclic guanosine monophosphate/nitric oxide pathway-related proteins was reduced. Taurine supplementation ameliorated erectile response as well as histologic and molecular alterations. CONCLUSION: Taurine supplementation improves erectile function in rats with DED probably by potential antifibrotic activity. This finding provides evidence for a potential new therapy for DED.
INTRODUCTION: For patients with diabetes, erectile dysfunction (ED) is common and greatly affects quality of life. However, these patients often exhibit a poor response to first-line oral phosphodiesterase type 5 inhibitors. AIM: To investigate whether taurine, a sulfur-containing amino acid, affects diabetic ED (DED). METHODS: Type 1 diabetes mellitus was induced in male rats by using streptozotocin. After 12 weeks, an apomorphine test was conducted to confirm DED. Only rats with DED were administered taurine or vehicle for 4 weeks. Age-matched nondiabetic rats were administered saline intraperitoneally for 4 weeks. MAIN OUTCOME MEASURES: Erectile function was evaluated by electrical stimulation of the cavernous nerve. Histologic and molecular alterations of the corpus cavernosum also were analyzed. RESULTS: Erectile function was significantly reduced in the diabeticrats compared with in the nondiabetic rats, and was improved in the diabeticrats treated with taurine. The corpus cavernosum of the rats with DED exhibited severe fibrosis and decreased smooth muscle content. Deposition of extracellular matrix proteins was increased in the diabeticrats, while expression of endothelial nitric oxide synthase/cyclic guanosine monophosphate/nitric oxide pathway-related proteins was reduced. Taurine supplementation ameliorated erectile response as well as histologic and molecular alterations. CONCLUSION:Taurine supplementation improves erectile function in rats with DED probably by potential antifibrotic activity. This finding provides evidence for a potential new therapy for DED.
Authors: Larissa E van Eijk; Annette K Offringa; Maria-Elena Bernal; Arno R Bourgonje; Harry van Goor; Jan-Luuk Hillebrands Journal: Adv Exp Med Biol Date: 2022 Impact factor: 3.650
Authors: Kai Cui; Yang Luan; Zhe Tang; Ke Rao; Tao Wang; Zhong Chen; Shaogang Wang; Jihong Liu; Daowen Wang Journal: PLoS One Date: 2017-01-19 Impact factor: 3.240